NVIDIA Earnings: What Watch for Feb. 25 Earnings Report
When NVIDIA reports earnings on Feb. 25, investors will scan every line for AI demand signals, margin trends, and gui...
Year End Tax Forms For Etfs
A quick guide to the year-end tax forms required for ETFs and tips to ensure correct reporting on your return.
24,251 articles
Mortgage Applications Slip 3.8% as Purchase Demand Stays
In the week ending June 12, 2026, mortgage applications slip 3.8% as purchase demand stays ahead of 2025, signaling a...
Why Calumet Stock Flopped Friday: What Investors Should Know
When a quarterly miss hits the wires, investors scramble to interpret the fallout. This deep dive explains why calume...
Can Oracle Reach $800 per Share by 2030? Here's How
Oracle just posted its strongest quarter ever with massive cloud backlog, yet investors face a capital-heavy path ahe...
Home Price Growth Out—and: What It Means for Loans in 2026
A fresh home price growth out—and signal is changing how buyers, homeowners, and lenders plan for 2026. This guide br...
Microsoft Fallen This Year: Catalysts to Rebound MSFT
Microsoft has fallen this year as AI hopes and cloud momentum wobble. Analysts highlight Azure, AI adoption, and cost...
Where Could Tesla Years Lead by 2028? A Base Case View
This article lays out a grounded three-year path for Tesla, focusing on core EV leadership, software-based autonomy r...
Intel Just 52-Week High: Buy, Hold or Sell at $140
Intel reached a fresh 52-week high as its foundry strategy gains traction and data-center demand strengthens. The sto...
Joint (JYNT) 2025 Earnings: Q4 Review and Outlook
A fresh, no-copy analysis of Joint (JYNT) 2025 earnings, focusing on Q4 results, margin trends, and the roadmap for 2...
Record Decline in Home Asking Prices Boosts Buyers
Home listings are cooling fast as sellers reset prices. The latest data show a record decline in home asking prices, ...
Harris: Rating Competitive Defense—7.1 Outlook for LHX
In a landscape defined by budget cycles and rapid tech shifts, L3Harris Technologies stands out with a 7.1 rating in ...
Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status